Canadian funding for the Toronto-based Structural Genomics Consortium (SGC) has been renewed, injecting $33 million into the ground breaking open innovation organization that determines the three-dimensional structure of proteins related to human diseases. The fourth phase of the public-private SGC will see an expansion its collaborative network to include disease and patient foundations while partnering with clinicians and research hospitals to validate new targets for drug discovery by testing its chemical probes on patients.